Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) fell by as much as 7% today in response to a broad corporate update. What's got investors riled up?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,